P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
作者： I. Skirnisdottir , B. Sorbe , T. Seidal
DOI: 10.1046/J.1525-1438.2001.01003.X
关键词: Oncology 、 Carcinoma 、 Survival analysis 、 Medicine 、 Bcl-2-associated X protein 、 Survival rate 、 Endometrioid tumor 、 Ovarian cancer 、 Internal medicine 、 Serous fluid 、 Ovarian carcinoma
摘要: The prognosis of ovarian carcinoma, even in the early stages (FIGO I-II), continues to present a challenge despite advances understanding pathophysiology and treatment. In series 106 patients with epithelial carcinomas FIGO IA-IIC, number prognostic factors (age, stage, histopathologic type, tumor grade) were studied relation important regulators apoptosis (p53, bcl-2, bax). Immunohistochemical techniques used. All received adjuvant radiotherapy after primary surgery. Univariate analysis showed that expression p53 was highly significantly associated grade (P = 0.007) survival status 0.046). Positive bcl-2 staining serous 0.0002) endometrioid subtypes, but not rate. A positive bax younger age 0.012) more favorable probability survival. significant association between tumors subtypes grades noted. most subgroup combination negative staining. multivariate Cox analysis, 0.0006) 0.020) independent factors.
sci-hub.se 参考文章(28)
Tapas Mukhopadhyay, Steven A. Maxwell, Jack A. Roth, Wild-Type versus Mutant p53 Springer Berlin Heidelberg. pp. 19- 54 ,(1995) , 10.1007/978-3-662-22275-1_3
Y T Tai, S Lee, E Niloff, C Weisman, T Strobel, S A Cannistra, BAX protein expression and clinical outcome in epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 16, pp. 2583- 2590 ,(1998) , 10.1200/JCO.1998.16.8.2583
Randall K. Gibb, Douglas D. Taylor, Tina Wan, Dennis M. O'Connor, David L. Doering, Çiçek Gerçel-Taylor, Apoptosis as a Measure of Chemosensitivity to Cisplatin and Taxol Therapy in Ovarian Cancer Cell Lines Gynecologic Oncology. ,vol. 65, pp. 13- 22 ,(1997) , 10.1006/GYNO.1997.4637
John P. Geisler, Hans E. Geisler, Michael C. Wiemann, Stanley S. Givens, Zhen Zhou, Greg A. Miller, Quantification of p53 in epithelial ovarian cancer Gynecologic Oncology. ,vol. 66, pp. 435- 438 ,(1997) , 10.1006/GYNO.1997.4799
P Athanassiadou, E Petrakakou, V Sakelariou, Ch Zerva, A Liossi, S Michalas, P Athanassiades, Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours. European Journal of Cancer Prevention. ,vol. 7, pp. 225- 231 ,(1998) , 10.1097/00008469-199806000-00007
J.S. Berek, O. Martínez-Maza, T. Hamilton, C. Tropé, J. Kaern, J. Baak, G.J.S. Rustin, Molecular and biological factors in the pathogenesis of ovarian cancer Annals of Oncology. ,vol. 4, pp. 77- 87 ,(1993) , 10.1093/ANNONC/4.SUPPL_4.S3
L HAVRILESKY, A ELBENDARY, J HURTEAU, R WHITAKER, G RODRIGUEZ, A BERCHUCK, Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstetrics & Gynecology. ,vol. 85, pp. 1007- 1010 ,(1995) , 10.1016/0029-7844(95)00058-Y
Michael A Levesque, Dionyssios Katsaros, He Yu, Paolo Zola, Piero Sismondi, Giorgio Giardina, Eleftherios P Diamandis, None, Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma Cancer. ,vol. 75, pp. 1327- 1338 ,(1995) , 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P
Fumio Yamasaki, Osamu Tokunaga, Hajime Sugimori, Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecologic Oncology. ,vol. 66, pp. 439- 448 ,(1997) , 10.1006/GYNO.1997.4783
Nadia Zaffaroni, Elvira Benini, Daniela Gornati, Alessandra Bearzatto, Rosella Silvestrini, Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures Stem Cells. ,vol. 13, pp. 77- 85 ,(1995) , 10.1002/STEM.5530130110